May 31 (Reuters) - Xilio Therapeutics Inc XLO.O:
XILIO THERAPEUTICS ANNOUNCES UPDATED PHASE 2 DATA FOR VILASTOBART, A TUMOR-ACTIVATED ANTI-CTLA-4, IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH METASTATIC MICROSATELLITE STABLE COLORECTAL CANCER
XILIO THERAPEUTICS INC - 26% RESPONSE RATE IN METASTATIC MSS CRC WITHOUT LIVER METASTASES
XILIO THERAPEUTICS INC - VILASTOBART AND ATEZOLIZUMAB SHOW WELL-TOLERATED SAFETY PROFILE
Source text: ID:nGNX9T0NBf
Further company coverage: XLO.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.